Affectis Pharmaceuticals AG Announces Target Validation Collaboration with Mitsubishi Pharma
08-Feb-2005
Today, one of the major challenges in developing optimised drugs against affective disorders is the limited availability of suitable animal models and sufficient expertise in selecting promising targets and leads as well as their preclinical development. Affectis´ team has experience in developing, performing and interpreting behavioural assays and animal models of diseases such as depression and anxiety.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.